Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders

Disclosed are novel piperazinyl-pyrazinone derivatives of formula (I) and methods of making them wherein: m is 1 or 2 n is 0, 1, 2, 3 or 4; R1 is H, alkyl, aryl-alkyl, heteroaryl-alkyl, 2-hydroxyethyl, methoxy-alkyl, alkyoxycarbonyl, aryloxy-alkyl or heteroaryloxy-alkyl; R2 and R3 each independently represent H or CH3; R4 and R5 each independently represent H, halogen, methyl, or together with the ring to which carbon atoms they are attached, form a 1H-quinoxalin-2-one nucleus; and R6 represents aryloxy, heteroaryloxy, arylthio, heteroarylthio, aryl-NH, heteroaryl-NH, aryl, aryl carbonyl, heteroaryl, or heteroarylcarbonyl. Compounds of the type disclosed are useful in the treatment of 5-HT2A receptor related disorders.